Core Viewpoint - On September 23, 2025, the company announced the decision to relieve Liu Yan from her position as the employee representative supervisor during the employee representative assembly [2] Company Summary - The company, Chenxin Pharmaceutical, held an employee representative assembly on September 23, 2025, where a resolution was passed to terminate Liu Yan's role as the employee representative supervisor [2]

Group 1 - The company, Chenxin Pharmaceutical, announced the election of Mr. Xubin Xu as the employee representative director of the fifth board of directors during the employee representative meeting held on September 23, 2025 [1]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-053 重要内容提示： 权益变动方向 比例增加□ 比例减少√ 权益变动前合计比例 6.11% 权益变动后合计比例 5.89% 本次变动是否违反已作出的承 诺、意向、计划 是□ 否√ 是否触发强制要约收购义务 是□ 否√ 投资者及其一致行动人的身份 □控股股东/实际控制人及其一致行动人 √其他 5%以上大股东及其一致行动人 □合并口径第一大股东及其一致行动人（仅适用 于无控股股东、实际控制人） □其他 （请注明） 2.信息披露义务人信息 | | | 3.一致行动人信息 公司持股 5%以上股东石家庄四药有限公司保证向本公司提供的信息真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 辰欣药业股份有限公司 | 信息披露义务人名称 | | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | --- | | 石家庄四药有限公司 | □ | 控股股东/实控人 | √ 91130100104406005 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-051 辰欣药业股份有限公司 关于取消职工代表监事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 辰欣药业股份有限公司 董事会 2025 年 9 月 23 日 1 / 1 为全面贯彻落实《中华人民共和国公司法》（以下简称《公司法》）、《上 市公司章程指引（2025年修订）》等法律、法规、规范性文件的规定，辰欣药业 股份有限公司（以下简称"公司"或"辰欣药业"）于2025年8月27日召开了第 五届董事会第九次会议、第五届监事会第九次会议，于2025年9月16日召开了20 25年第二次临时股东大会，会议分别审议通过了关于公司不再设立监事会及监事 和修改《辰欣药业股份有限公司章程》的相关事项。 根据修订后的《辰欣药业股份有限公司章程》相关规定，公司不再设立监事 会及监事。2025年9月23日，公司召开了职工代表大会，大会决议同意解除刘岩 女士的辰欣药业职工代表监事的职务。 刘岩女士职工代表监事的原定任期到期日为2027年2月28日，不存在应当履 行而未履行的承诺 ...

证券代码：603367 证券简称：辰欣药业 公告编号：2025-052 辰欣药业股份有限公司 关于公司董事离任暨选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 辰欣药业股份有限公司（以下简称"公司"或"辰欣药业"）董事会 2025 年 9 月 23 日收到董事续新兵先生的辞呈，续新兵先生因工作调整，辞去公司董 事、董事会薪酬与考核委员会委员职务，并确认与公司董事会无意见分歧，亦无 需提请公司股东和债权人关注的事宜。续新兵先生辞任后，继续担任公司及公司 控股子公司的其他职务。2025 年 9 月 23 日，公司召开职工代表大会，决议选举 续新兵先生为职工代表董事。 二、职工代表董事选举情况 为进一步完善公司治理结构，根据《中华人民共和国公司法》《上市公司章 程指引》等法律法规和规范性文件以及《公司章程》的相关规定，公司董事会中 设 1 名职工代表董事，由职工代表大会选举产生。 公司于 2025 年 9 月 23 日召开职工代表大会，经全体与会职工代表审议并表 决，选举续新兵先生（简历附后） ...

Core Viewpoint - Chenxin Pharmaceutical (603367.SH) announced a share reduction by a major shareholder, Shijiazhuang Four Pharmaceutical Co., Ltd., which sold 1 million shares, representing 0.221% of the company's total share capital [1] Shareholder Activity - On September 22, 2025, Shijiazhuang Four Pharmaceutical Co., Ltd. reduced its holdings from 27,661,441 shares to 26,661,441 shares [1] - The shareholding percentage decreased from 6.11% to 5.89%, marking a change that touches the 1% threshold [1]

Core Viewpoint - Chenxin Pharmaceutical has shown significant stock performance with a year-to-date increase of 60.13%, despite a recent decline over the past 20 days [1][2]. Group 1: Stock Performance - On September 18, Chenxin Pharmaceutical's stock rose by 2.07%, reaching 21.65 CNY per share, with a trading volume of 1.59 billion CNY and a turnover rate of 1.64%, resulting in a total market capitalization of 9.802 billion CNY [1]. - The stock has experienced a 1.26% increase over the last five trading days, a 27.83% decrease over the last 20 days, and a 56.32% increase over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on September 3, where it recorded a net purchase of 51.8339 million CNY [1]. Group 2: Financial Performance - For the first half of 2025, Chenxin Pharmaceutical reported a revenue of 1.740 billion CNY, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million CNY, down 15.23% year-on-year [2]. - The company has distributed a total of 1.112 billion CNY in dividends since its A-share listing, with 548 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Chenxin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 shares held per shareholder, a decrease of 40.50% [2]. - Hong Kong Central Clearing Limited is the seventh-largest circulating shareholder, holding 6.9075 million shares, an increase of 1.9689 million shares from the previous period [3].

Company Overview - Chanshin Pharmaceutical Co., Ltd. is located at No. 16 Tongji Road, High-tech Zone, Jining City, Shandong Province, established on November 6, 1998, and listed on September 29, 2017 [2] - The company's main business involves research, development, and production of chemical drug formulations, with revenue composition as follows: large-volume injections 42.66%, small-volume injections 29.80%, oral solid preparations 13.98%, drops 4.31%, lyophilized powder injections 3.68%, ointments 3.43%, raw materials 1.35%, rinsing agents 0.59%, and others 0.20% [2] - Chanshin Pharmaceutical belongs to the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and chemical formulations, with concepts including heparin, anti-influenza, small-cap, biomedicine, and innovative drugs [2] Financial Performance - For the first half of 2025, Chanshin Pharmaceutical achieved operating revenue of 1.74 billion yuan, a year-on-year decrease of 15.97%, and a net profit attributable to shareholders of 229 million yuan, a year-on-year decrease of 15.23% [2] - The company has distributed a total of 1.112 billion yuan in dividends since its A-share listing, with 548 million yuan distributed in the last three years [3] Stock Performance - As of September 17, Chanshin Pharmaceutical's stock price was 21.17 yuan per share, with a market capitalization of 9.585 billion yuan [1] - The stock has increased by 56.58% year-to-date, but has seen a decline of 30.93% over the past 20 days [1] - The company has appeared on the trading leaderboard four times this year, with the most recent appearance on September 3, where it recorded a net purchase of 51.83 million yuan [1] Shareholder Information - As of June 30, 2025, the number of shareholders for Chanshin Pharmaceutical was 35,900, an increase of 68.07% from the previous period, with an average of 12,602 circulating shares per person, a decrease of 40.50% [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the seventh largest, holding 6.9075 million shares, an increase of 1.9689 million shares from the previous period [3]

Meeting Overview - The second extraordinary general meeting of shareholders was held on September 16, 2025, at the company's office in Jining, Shandong Province [2] - The meeting was convened by the board of directors and chaired by Chairman Du Zhenxin, utilizing a combination of on-site and online voting methods [2][3] Attendance and Voting - All current directors (9) and supervisors (3) attended the meeting, along with the board secretary and other senior management [3][4] - No resolutions were rejected during the meeting [2] Resolutions Passed - The following key resolutions were approved: - Amendments to the Articles of Association and its attachments [3] - Amendments to the Rules of Procedure for Shareholders' Meetings [3] - Amendments to the Rules of Procedure for Board Meetings [4] - Amendments to the Independent Director Work System [4] - Establishment of Implementation Details for Cumulative Voting System [4] - Amendments to the Decision-Making System for External Guarantees [4] - Amendments to the Management System for the Appointment of Accounting Firms [4] - Establishment of the Compensation Management System for Directors and Senior Management [4] - Establishment of Behavior Norms for Controlling Shareholders and Actual Controllers [4] - Amendments to the Related Party Transaction Decision-Making System [5] - Amendments to the Fundraising Management Measures [5] - Abolishment of the Rules of Procedure for Supervisory Meetings [5] - Resolution to abolish the supervisory board and supervisors [5] - Resolution to permanently supplement remaining funds from fundraising projects into working capital [5] Legal Verification - The meeting was witnessed by lawyers from Shandong Guoyao Qindao (Jinan) Law Firm, confirming that the meeting's procedures complied with relevant laws and regulations [6] - The legal opinion concluded that the qualifications of the convenor and attendees were valid, and the voting procedures and results were lawful and effective [6]

证券代码：603367 证券简称：辰欣药业 公告编号：2025-050 辰欣药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 16 日 (一)非累积投票议案 1、 议案名称：《关于修订＜公司章程＞及其附件的议案》 1.01、《关于修订＜公司章程＞的议案》 (二)股东大会召开的地点：山东省济宁市高新区同济路 16 号辰欣药业股份有限 公司一园区办公楼六楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 209 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 204,974,370 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 45.2727 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会 ...